# A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

Source: https://onco.cc/trials/nct07169734/  
OnCo record `nct07169734` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ALE.P03 in non-small-cell lung cancer, colorectal cancer, biliary tract cancer and bladder & urothelial cancer, run by Alentis Therapeutics AG, now recruiting.

## Summary

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors is a phase 1/2 interventional study registered as NCT07169734 by Alentis Therapeutics AG, with 180 participants planned, started 2025-08-26 and due to reach its primary completion in 2029-04-05. Interventions recorded: ALE.P03.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07169734
- Phase: 1/2
- Setting: A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- Sponsor: Alentis Therapeutics AG
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07169734: https://clinicaltrials.gov/study/NCT07169734

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Alentis Therapeutics](https://onco.cc/companies/alentis-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07169734.json